Sorrento Therapeutics, Inc. announced that it has received clearance from the FDA for its investigational new drug application for Abivertinib or the Phase II MAVERICK study to be conducted in participants with metastatic CRPC at multiple centers in the United States.
[Sorrento Therapeutics, Inc.]